Kornimate/medical-research-clean huggingface dataset:
the relevance between the microrna-30e in plasma and the prognosis of schizophrenia patients

Conditions: Schizophrenia; Micrognathia

Summary: this study investigates the relationship of circulating microrna-30e and schizophrenia, and shows the relevance of the aberrant microrna-30e expression in plasma with the variation disease status.

the plasma samples from 15 individuals with schizophrenia (with a diagnosis of icd-10) and the equivalent healthy controls will be conducted with the quantification analysis of the microrna-30e via real-time quantitative polymerase chain reaction(rt-pcr). the 15 patients enrolled should be the first-episode and have not been treated, or were drug free 3 months recently at least. this research measures the expression level of microrna-30e in schizophrenia respectively before the beginning treatment with atypical psychotics or combined with mect, after the 4-week treated , the 8-week treated compared with 15 healthy controls.

Eligibility criteria:
inclusion criteria: * persons should be diagnosed with schizophrenia according to the international statistical classification of diseases and related health problems 10th revision (icd-10) * the first-onset or drug-free in the latest 3 months * between the ages of 17-40 exclusion criteria: * comorbid with other psychosis * have physical or neurological diseases such as traumatic brain injuries * history of drug-abused or alcoholic * blood transfusion history in a month * been treated with modified electric convulsive therapy(mect) in late 3 months
epigenetic regulation of bdnf in major depression

Conditions: Major Depressive Disorder

Summary: the investigators will (1) detect the associations between brain-derived neurotrophic factor (bdnf) dna methylation, histone modification, depressive symptoms, suicidal behavior and antidepressant responses in major depressive disorder (mdd) patients, (2) check the correlation between blood bdnf protein and rna and bdnf rs6265 gene, and (3) discuss the possible mechanisms of epigenetic regulation of bdnf in taiwanese major depressive patients.

brain-derived neurotrophic factor (bdnf) had been chosen as a candidate gene for a development of major depressive disorder (mdd). bdnf had been reported to have an important role on neuronal plasticity, axonal growth and connectivity, and participating in the local response to various types of neuronal stressors. bdnf also influences the differentiation of neurons. in the past studies, the investigators had found that major depressive women had lower serum bdnf protein levels than healthy controls, and their bdnf levels became significantly increased after antidepressant treatments. in addition, some authors had found that reduced expression of bdnf was noted in postmortem brain of completed suicide subjects. suicidal major depressive patients also had lower plasma bdnf levels than non-suicidal major depressive patients. these findings suggested that bdnf might play an important role in the suicidal behavior. however, in past studies, the results did not fully explain why major depressive patients with same genotypes had different clinical expression, including the severity of depression, with/without suicide, and the treatment response. recently, some papers found that there were relationships between epigenetic regulation, including dna methylation and histone modification, and psychopathology of major depression. therefore, we try to investigate the relationships between epigenetic regulation of bdnf and major depression.

Eligibility criteria:
inclusion criteria: the clinical screening and assessment in patients with major depression： 1. 40 major depression will be recruited in psychiatric inpatients according to dsm-iv criteria by a semi-structured interview. the assessment will be done by two senior psychiatrists. the intra-rater and inter-rater reliability will be done before this project started. 2. the patients had the ability to complete the written inform consent. 3. the choice of antidepressant drugs depended on the need of patients in natural treatment procedure. they included selective serotonin reuptake inhibitors (ssri), eg. fluoxetine or paroxetine. 4. the 17-item hamilton depression rating scale (ham-d) was used to assess severity of depression. the minimum baseline score of the 17-item ham-d was 18. exclusion criteria: 1. the patients had systemic diseases, including metabolic, heart, and liver diseases。 2. the patients had received any drugs before entering this protocol. 3. the patients were heavy smokers or dependent on alcohol. 4. the use of secondary generation anti-psychotic drugs and mood stabilizers.

Keywords: major depression bdnf dna methylation histone modification
should palatine tonsils be included in the oropharyngeal swab for sars-cov-2 molecular testing?

Conditions: SARS-CoV Infection; Coronavirus; Corona Virus Infection

Summary: citizens who undergo testing for covid-19 at one of two testcenters in copenhagen captial region will be invited to participate in the study. the participants will be randomized to either an oropharyngeal swap including the palatine tonsils or an oropharyngeal swap without the palatine tonsils for sars-cov-2 testing. the swabs will be sent to the clinical microbiology laboratory for sars-cov-2 detection using rt-pcr. the diagnostic accuracy and sars-cov-2 viral load will be compared. the participants will be asked to complete a questionnaire regarding their symptoms.

we will include citizens referred for outpatient testing for covid-19 who will be offered to participante in the study on a volunteer basis. participants are all volunteers, who are attending the test facilities to obtain a pcr test. participants are required to provide oral and written informed consent to participate before entering the study. the inclusion criterion is 18 years or more of age. exclusion criteria are neck breathers (tracheostomy/laryngectomy patients). the participants will be randomized to either an oropharyngeal swap including the palatine tonsils or an oropharyngeal swap without the palatine tonsils for sars-cov-2 testing. the swabs will be sent to the clinical microbiology laboratory for sars-cov-2 detection using rt-pcr as usual. the diagnostic accuracy and sars-cov-2 viral load will be compared using independent t-test. the participants will be asked to complete a questionnaire regarding their symptoms and the number of sick days. all data will be documented on-site in a secure web database (redcap). the primary outcome will be reported as: • sars-cov-2 rna by rt-pcr test result (positive, negative, inconclusive) the secondary outcome will be reported as: * sars-cov-2 rt-pcr cycle threshold (ct) value * test discomfort on a 11-point nrs-scale * development of covid-19 disease after testing * sars-cov-2 detection rate for each healthcare worker * mallampati score of participants being tested

Eligibility criteria:
inclusion criteria: * citizens referred for outpatient testing for covid-19 in valby and hillerød covid-19 testcenter. exclusion criteria: * age under 18 years * neck breathers (tracheostomy/laryngectomy patients)
a study to evaluate the effectiveness of the induced reflex cough test plus urodynamics to identify stress urinary incontinence in female subjects with a history of stress urinary incontinence

Conditions: Stress Urinary Incontinence

Summary: this study is to evaluate the effectiveness of identifying stress urinary incontinence (sui) in female subjects using the induced reflex cough test (irct) administered with urodynamic testing by evaluation of sensitivity and specificity.


Eligibility criteria:
inclusion criteria: * women \>25 years of age * history of sui (except for healthy controls) * healthy or stable medical problems (no change in 3 months) * willingness and ability to undergo all the study procedures * stable medications are allowed except for prescription and over-the-counter medications with anticholinergic or α-agonistic properties that can affect the bladder or urethra; these must be discontinued at least 2 weeks prior to evaluation * able to understand and sign the informed consent document. exclusion criteria: * body mass index (bmi) \>40 * history of severe arthritis of the hips, knees, or feet that could limit mobility during the study * prior treatment of any kind (surgical or pharmacologic) for incontinence at least 30 days before the cough testing session including treatment with slings, botox, interstim and all bulking agents * prior pelvic radiation * post-void residual urine \>100 ml at screening * pelvic organ prolapse quantification (pop-q) stage \>2 * positive urine culture at screening or dip stick for \>1+ leukocyte esterase on the day of the procedures * positive pregnancy test * evidence of infection with hepatitis or human immunodeficiency virus (hiv) * dementia * clinically significant changes on the electrocardiogram (ecg) in women \>50 years of age or in the clinical laboratory values as determined by the investigator * history of urge symptoms, diagnosis of interstitial cystitis, irritable bowel disease (requiring medications) * history of neurological deficit or injury that could affect laryngeal cough reflex, for example, central nervous system related conditions such as stroke or multiple sclerosis, head and neck cancer, major laryngeal surgery * history of neurological disorders leading to bladder abnormalities including stroke, parkinsonism, multiple sclerosis, spinal cord surgery or spinal cord injury * active hemorrhoids or history of recent (within 1 year) rectal surgery * previous major pelvic or abdominal surgery (within 6 months) * tobacco smokers and non-smokers who have \>15 pack-year history or frequent (\>2 times per week) marijuana smoking * active sexually transmitted disease or genital herpes outbreak or symptomatic pelvic inflammatory disease * pessary in place

Keywords: stress urinary incontinence
iron & vitamin c study

Conditions: Spinal Cord Injury

Summary: iron overload is a life-threatening condition that can lead to liver disease, cardiac disease, diabetes and arthritis. simultaneous supplementation with both iron and aa may place individuals with sci at risk for iron overload as well as oxidative damage by iron-generated free radicals. both conditions of high and low iron stores may present with common signs and symptoms. accurate diagnosis of iron disorder should consider crp, hematocrit, hemoglobin, serum iron, tibc, percent saturation of iron binding capacity, serum ferritin and hepcidin. the investigators are proposing a study to determine the effect of concurrent aa and iron supplementation on iron status of individuals with sci. the investigators goal is to identify abnormal status that may be attributed to simultaneous supplementation of iron and aa to develop future supplementation protocols in this population for optimal iron status.


Eligibility criteria:
inclusion criteria: 1. male 2. 18 years to 90 years of age 3. medically stable 4. chronic sci (\>6 months post injury) without regard to the level or completeness of lesion 5. supplementation with: * a standard recommended dose of 120-200 mg oral elemental iron (tablet or liquid; ferrous sulfate, fumarate or gluconate forms) for a minimum of 6 months; or * a standard recommended dose of 250-2,000 mg aa per day for a minimum of 6 months; or * both 120-200 mg oral elemental iron and 250-2,000 mg aa per day for a minimum of 6 months. 6. veteran exclusion criteria: acute cardiovascular, pulmonary or renal conditions

Keywords: spinal cord injuries ascorbic acid vitamin c iron dietary supplements
straberi epistamp needling treatment for skin rejuvenation

Conditions: Wrinkle; Elastic Skin; Collagen Degeneration

Summary: this pilot study will expand knowledge and application needling using the epistamp device for the improvement of a new vitalized epidermal layer with new vibrant active cells, supported by more robust collagen and elastin fine lines, deep wrinkles, and collagen production.

this pilot study will expand the knowledge and application needling using the epistamp device and its benefits for improving the appearance of fine lines, deep wrinkles, and collagen production. the pilot aims to objectively measure skin quality using the derma scan, photographs and provide objective data showing improvement by way of the universal skincare institute blood flow scale.

Eligibility criteria:
inclusion criteria: * derma scan showing aging including skin texture, wrinkles, brown spots, and pores. * patients willing to sign informed consent. * patients willing to be photographed and video documented * patients willing to consent to 3 months of treatment exclusion criteria: * history of eczema in the treatment area; psoriasis and any other chronic skin conditions * history of actinic (solar) keratosis in the treatment area; * history of hemophilia * history of diabetes * the presence of raised moles, warts on the targeted area. * collagen vascular diseases or cardiac abnormalities * blood clotting problems * active bacterial or fungal infection * facial melanosis * malignant tumors * immunosuppression * use of blood thinners or prednisone * corticosteroids within two weeks of the procedure * chronic liver disease * porphyria or other skin diseases. * patient not willing to sign informed consent. * tca peels in the last 5 weeks * subject currently has moderate to severe acne on the face. * microneedling within the last 6 months * subject has an active infection. * subject has a history of a bleeding disorder * subject has a history of keloidal tendency * subject has received ablative or non-ablative laser treatments in the previous 6 months. * subject has taken accutane within the previous 3 months.

Keywords: microneedling
the clinical effect of different lateral retinaculum relaxation methods in the treatment of lpcs

Conditions: Lateral Patellar Compression Syndrome

Summary: to observe the comparison of the clinical effects of two different ways of loosening the lateral support band under arthroscopy to treat lateral patella excessive compression syndrome.

to analyze the surgical conditions of 64 patients with lateral patella excessive compression syndrome who were surgically treated by deputy chief physician yang yuping of the department of sports medicine, peking university third hospital from september 2004 to january 2019. among them, 24 early cases used the traditional proximal release of the lateral retinaculum (traditional surgical group), and recently 40 cases, after learning from the surgical experience of the early cases, switched to the lateral release of the lateral retinaculum, that is, "l" type release (new surgery group). the visual analog scale (vas), lysholm score, and ikdc knee function subjective evaluation scale (ikdc) score were performed before and after the operation. by analyzing the knee movement scores of patients before and after surgery, the efficacy of the above two operations was judged, and the two groups of postoperative scores were evaluated.

Eligibility criteria:
inclusion criteria: * from september 2004 to january 2019, patients with lateral patella overcrowding syndrome treated by deputy chief physician yang yuping of the department of sports medicine, peking university third hospital exclusion criteria: * from september 2004 to january 2019, patients with lateral patella overcrowding syndrome treated by deputy chief physician yang yuping of the department of sports medicine, peking university third hospital
to study gsp 301 in patients with seasonal allergic rhinitis

Conditions: Seasonal Allergic Rhinitis

Summary: study to evaluate the two different strengths and dose regimen of gsp 301 to be effective in treatment of seasonal allergic rhinitis.


Eligibility criteria:
key inclusion criteria: 1. aged ≥12 years and older inclusive of either sex. 2. documented clinical history of sar (for at least 2 years preceding the screening visit \[visit 1\]) with exacerbations (clinical evidence of active symptoms) during the study season for the mountain cedar pollen 3. a 12-hour reflective tnss ≥ 8 out of a possible 12 and a congestion score of ≥ 2 for the am assessment at the screening visit (visit 1). key exclusion criteria: 1. pregnant or lactating women. 2. plans to travel outside the known pollen area for the investigative site for \> 24 hours during the last 7 days of run in period. 3. history of nasal polyps of other clinically significant respiratory tract malformations, recent nasal biopsy, nasal trauma (such as nasal piercing) or surgery, atopic dermatitis or rhinitis medicamentosa. 4. history of anaphylaxis and/or other severe local reaction(s) to skin testing. 5. history of positive test for hiv, hepatitis b or hepatitis c infection. 6. documented evidence of acute or significant chronic sinusitis or chronic purulent postnasal drip. 7. subjects with an active pulmonary disorder or infection. 8. subjects with posterior subcapsular cataracts or glaucoma.
efficacy and safety of conbercept for diabetic macular edema combined with severe non-proliferative diabetic retinopathy

Conditions: Diabetic Macular Edema

Summary: the goal of this prospective multicenter open label study is to evaluate the efficacy and safety of intravitreal injection conbercept (ivc) for the treatment of diabetic macular edema (dme) combined with severe nonproliferative diabetes retinopathy (snpdr). the main questions it aims to answer are: * mean changes in best corrected visual acuity (bcva) and central macular thickness (cmt) in comparison with baseline at 12 months after initial treatment * proportion of eyes with visual gain ≥15 letters in early treatment diabetic retinopathy study (etdrs) chart and ≥2-step improvement in diabetic retinopathy severity scale (drss) score after 12 months of the treatment * proportion of eyes actually underwent prp treatment after 3 and 12 months of the treatment * mean changes in bcva and cmt from baseline to monthly follow-up time point * complications and adverse effects


Eligibility criteria:
inclusion criteria: * symptomatic patients aged 18 years or above with center involved diabetic macular edema in the involved eye and without clinically significant diabetic macular edema in the fellow eye defined on the basis of spectral-domain optical coherence tomography (oct) * central macular thickness (cmt) ≥300 μm measured by oct * the involved eyes diagnosed as severe non-proliferative diabetic retinopathy (snpdr) confirmed by two independent experienced ophthalmologists based on the etdrs standard seven field color fundus photographs exclusion criteria: * concomitant or previous macular diseases that may hinder visual improvement other than diabetic retinopathy (e.g., retinal vein occlusion, age-associated macular degeneration, uveitis, vitreomacular traction or epiretinal membrane) * history of glaucoma or optic neuropathy of any kind * previous vitreoretinal surgery or pan-retinal photocoagulation * intravitreal injection anti-vegf drugs within 6 months or intravitreal injection glucocorticoid within 3 months * macular focal/grid laser photocoagulation within 3 months
efficacy and safety of pyrotinib in her2 positive gastrointestinal tumors

Conditions: Gastrointestinal Tumor; Effect of Drug

Summary: targeting human epidermal factor receptor 2 (her2) therapy have shown the anti-tumor efficacy in patients with her2-positive gastrointestinal tumors. pyrotinib is an irreversible small-molecule receptor tyrosine kinase inhibitor targeting both epidermal growth factor receptor (egfr) and her2. this study is designed to evaluate the efficacy and safety of pyrotinib in patients with her2 positive gastrointestinal tumors.

this study is designed to evaluate the efficacy and safety of pyrotinib in patients with her2 positive gastrointestinal tumors. three cohorts were designed for this trial. cohort 1: patients with gastric cancer or esophageal adenocarcinoma receiving paclitaxel combined with pyrotinib for second-line therapy; cohort 2: patients with gastric cancer or esophageal adenocarcinoma receiving pyrotinib monotherapy for third-line or posterior line therapy; cohort 3: patients with colorectal cancer receiving pyrotinib combined with/without trastuzumab for third-line or posterior line therapy.

Eligibility criteria:
inclusion criteria: 1. aged ≥18 2. ecog performance status of 0 to 1. 3. life expectancy of more than 12 weeks. 4. at least one measurable lesion exists.(recist 1.1) histologically or cytologic confirmed her2 positive gastrointestinal tumors who failed prior therapies. 5. required laboratory values including following parameters: anc: ≥ 1.5 x 10\^9/l, platelet count: ≥ 80 x 10\^9/l, hemoglobin: ≥ 90 g/l, total bilirubin: ≤ 1.5 x upper limit of normal, uln, alt and ast: ≤ 1.5 x uln, bun and creatine clearance rate: ≥ 50 ml/min lvef: ≥ 50% qtcf: \< 470 ms 6. signed informed consent. exclusion criteria: 1. subjects with third space fluid that can not be controled by drainage or other methods. 2. subjects that are unable to swallow tablets, or dysfunction of gastrointestinal absorption. 3. less than 4 weeks from the last radiotherapy, chemotherapy, target therapy 4. subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. subjects who can not interrupt the using of the drugs that may cause qt prolongation during study. 5. receiving any other antitumor therapy. 6. known history of hypersensitivity to pyrotinib or any of it components. ongoing infection (determined by investigator). 7. history of immunodeficiency, including hiv-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. 8. subjects had any heart disease, including: (1) angina; (2) requiring medication or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) any heart diseases judged by investigator as unsuitable to participate in the trial. 9. female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test. 10. known history of neurological or psychiatric disease, including epilepsy or dementia.

Keywords: pyrotnib, her2, gastrointestinal tumor, phase ii
treatment of il-6 and its receptor antagonists in children's severe sepsis.

Conditions: Critical Illness Sepsis, Severe

Summary: in severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. however, the role of il-6 and its receptor antagonists in patients with severe sepsis and septic shock is discussed controversially. to date, the efficacy and safety of il-6 and its receptor antagonists in children with severe infection is not fully evaluated.

the investigators intend to enroll all children who were hospitalized in pediatric intensive care unit of children's hospital of fudan university from january 2022 to december 2023. children with a picu length of day less than 48h will be excluded. patients who met the inclusion criteria will be divided into trial group and control group. clinical and demographic data, as well as treatment outcome will be collected from the electronic health record.

Eligibility criteria:
inclusion criteria: * 1.children between 29 days and 18 years old. 2.severe pneumonia and/or sepsis.patients were included who meet the guideline for diagnosis and treatment of community-acquired pneumonia in children (2019) issued by the national health commission of the people's republic of china and/or who meet the international guide to the 2020 campaign to save sepsis: management of septic shock and sepsis-related organ dysfunction in children. exclusion criteria: * 1.notifiable infectious diseases. 2.the researcher believes that he is not suitable to participate in other situations in this study. 3.participants in other clinical trials in the same period. 4. discharge within 48 hours.

Keywords: critical illness, sepsis, children, tocilizumab, siltuximab